Abstract:Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease characterized by eosinophil-rich granulomatous inflammation and necrotizing vasculitis, pre-dominantly affecting small-to-medium-sized vessels. It is categorized as a primary antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) but also shares features of hypereosinophilic syndrome (HES); therefore, both vessel inflammation and eosinophilic infiltration are suggested to cause organ damage. This dual nature of the disease causes variable clinical presentation. As a result, careful differentiation from mimicking conditions is needed, especially from HES, given the overlapping clinical, radiologic, and histologic features, and biomarker profile. EGPA also remains a diagnostic challenge, in part because of asthma, which may pre-dominate for years, and often requires chronic corticosteroids (CS), which can mask other disease features. The pathogenesis is still not fully understood, however, the interaction between eosinophils and lymphocytes B and T seems to play an important role. Furthermore, the role of ANCA is not clear, and only up to 40% of patients are ANCA-positive. Moreover, two ANCA-dependent clinically and genetically distinct subgroups have been identified. However, a gold standard test for establishing a diagnosis is not available. In practice, the disease is mainly diagnosed based on the clinical symptoms and results of non-invasive tests. The unmet needs include uniform diagnostic criteria and biomarkers to help distinguish EGPA from HESs. Despite its rarity, notable progress has been made in understanding the disease and in its management. A better understanding of the pathophysiology has provided new insights into the pathogenesis and therapeutic targets, which are reflected in novel biological agents. However, there remains an ongoing reliance on corticosteroid therapy. Therefore, there is a significant need for more effective and better-tolerated steroid-sparing treatment schemes.

Advances in Research on Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis

Eosinophil extracellular traps in respiratory ailment: Pathogenic mechanisms and clinical translation

Role of eosinophil extracellular traps in the pathogenesis of chronic airway diseases

Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis

Role of the Extracellular Traps in Central Nervous System

Advances in neutrophil extracellular traps in systemic juvenile idiopathic arthritis

Eosinophil extracellular vesicles and DNA traps in allergic inflammation

Eosinophil extracellular traps in a patient with chronic eosinophilic pneumonia

Eosinophilic granulomatosis with polyangiitis – Advances in pathogenesis, diagnosis, and treatment

The Expanding Role of Extracellular Traps in Inflammation and Autoimmunity: The New Players in Casting Dark Webs

Eosinophil extracellular traps in eosinophilic chronic rhinosinusitis induce Charcot-Leyden crystal formation and eosinophil recruitment

Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis

Macrophage Extracellular Traps: Current Opinions and the State of Research regarding Various Diseases

Genetic and Non-Genetic Contributions to Eosinophilic Granulomatosis with Polyangiitis: Current Knowledge and Future Perspectives

The Role and Mechanism of Extracellular Traps in Chronic Rhinosinusitis

[Research progress on neutrophil extracellular traps in tumor].

Neutrophil Extracellular Traps and the Effects in Related Diseases

Neutrophil Extracellular Traps: Signaling Properties and Disease Relevance

Neutrophil extracellular traps - an a-list-actor in a variety of diseases

International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis

[Eosinophilic granulomatosis with polyangiitis: a review article]